| __timestamp | AstraZeneca PLC | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5579000000 | 45967000 |
| Thursday, January 1, 2015 | 5997000000 | 114737000 |
| Friday, January 1, 2016 | 5890000000 | 183204000 |
| Sunday, January 1, 2017 | 5757000000 | 231644000 |
| Monday, January 1, 2018 | 5932000000 | 293998000 |
| Tuesday, January 1, 2019 | 5958000000 | 357355000 |
| Wednesday, January 1, 2020 | 5991000000 | 412084000 |
| Friday, January 1, 2021 | 9736000000 | 497153000 |
| Saturday, January 1, 2022 | 9762000000 | 705789000 |
| Sunday, January 1, 2023 | 10935000000 | 648449000 |
| Monday, January 1, 2024 | 13583000000 |
Unleashing the power of data
In the ever-evolving pharmaceutical landscape, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, AstraZeneca PLC and Ultragenyx Pharmaceutical Inc. have demonstrated contrasting approaches to R&D investment.
From 2014 to 2023, AstraZeneca's R&D expenses surged by nearly 96%, peaking in 2023 with a remarkable $10.9 billion investment. This reflects AstraZeneca's strategic focus on expanding its drug pipeline and enhancing its competitive edge. In contrast, Ultragenyx, a smaller player, increased its R&D spending by over 1,300% during the same period, reaching $648 million in 2023. This underscores Ultragenyx's aggressive push to innovate in niche markets.
These trends highlight the diverse strategies employed by pharmaceutical giants and emerging companies alike, as they navigate the complex terrain of drug development and market competition.
Research and Development Expenses Breakdown: AstraZeneca PLC vs Zoetis Inc.
AstraZeneca PLC vs Verona Pharma plc: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for AstraZeneca PLC and Rhythm Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for AstraZeneca PLC and Iovance Biotherapeutics, Inc.
Research and Development Investment: AstraZeneca PLC vs Celldex Therapeutics, Inc.
Research and Development: Comparing Key Metrics for argenx SE and Ultragenyx Pharmaceutical Inc.
R&D Insights: How Jazz Pharmaceuticals plc and Ultragenyx Pharmaceutical Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Halozyme Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc.
R&D Spending Showdown: Blueprint Medicines Corporation vs Ultragenyx Pharmaceutical Inc.
Amneal Pharmaceuticals, Inc. or Ultragenyx Pharmaceutical Inc.: Who Invests More in Innovation?
Comparing Innovation Spending: Ultragenyx Pharmaceutical Inc. and Vericel Corporation
R&D Spending Showdown: Ultragenyx Pharmaceutical Inc. vs Xencor, Inc.